CSTL Overview

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is47.20 USD with a low forecast of 41.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Castle Biosciences Inc revenue for the last quarter amounts to 83.68M USD, decreased -4.90

Castle Biosciences Inc. EPS for the last quarter amounts to -0.49 USD, decreased -45.56

Castle Biosciences Inc (CSTL) has 883 emplpoyees as of May 15 2026.

Today CSTL has the market capitalization of 572.63M USD.